A recent study conducted on ER+ advanced breast cancer patients treated with a combination of the CDK4/6 inhibitor ribociclib and letrozole showed that loss of PTEN expression due to AKT activation could lead to the development of resistance to CDK4/6 inhibition [51]. This evidence concerns the gene AKT1 and breast carcinoma.